jRCT2031230690进行中（未招募）不适用
An open-label, uncontrolled, single-arm study of NT 201 in patients with cervical dystonia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 22
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 75age old under（—）
- 性别
- All
入选标准
- •The investigator will select subjects for Group A who meet all of the following criteria (1) to (10).
- •(1) Patients whose written informed consent has been obtained before participating in this study
- •(2) Patients aged 18 to 75 years at the time of informed consent
- •(3) A clinical diagnosed of cervical dystonia
- •(4) TWSTRS - total score >= 20 at the screening test
- •(5) TWSTRS - severity score >= 10 at the screening test
- •(6) TWSTRS - disability score >= 3 at the screening test
- •(7) TWSTRS - pain score >= 1 at the screening test
- •(8)For patients treated with a botulinum toxin therapy for cervical dystonia: At least 10 weeks must have been passed between the last injection with botulinum toxin for cervical dystonia and the screening test (The screening test can be conducted on the same day of the next 10 weeks or later after the last injection)
- •(9)For patients treated with a botulinum toxin therapy for cervical dystonia: The effect of the most recent botulinum treatment has disappeared in terms of the TWSTRS score at the time of the screening test, and the investigator has determined that the next botulinum toxin injection is required
- •(10)For patients treated with a botulinum toxin therapy for cervical dystonia: The investigator has determined that the therapeutic effect of the botulinum toxin preparation has been obtained with the most recent injection
- •The investigator will select subjects for Group B who meet all of (1), (2), (4) to (10), and the following criteria (11).
- •(11) A clinical diagnosed of tardive torticollis
排除标准
- •[Exclusion criteria applicable to Group A and Group B]
- •(1) Traumatic torticollis and congenital torticollis
- •(2) Patients who only have symptoms of anterocollis, or among patients with symptoms other than anterocollis, patients with a TWSTRS - severity score for anterocollis >= 2 at the screening test
- •(3) Patients with a history of deep brain stimulation therapy, intrathecal baclofen therapy, or surgical therapy for cervical dystonia (myotomy, selective peripheral nerve blockade, etc.)
- •(4) Marked limitation on passive range of cervical motion that suggests contractures or other malformations
- •(5) Patients with systemic neuromuscular junction disorders (myasthenia gravis, Lambert-Eaton syndrome, etc.), patients with amyotrophic lateral sclerosis
- •(6) Treatment with botulinum toxins for any injection other than cervical dystonia within 16 weeks prior to baseline
- •(The screening test can be conducted on the same day of the next 16 weeks or later after the last injection)
- •(7) Patients who have been judged by the investigator to have had primary or secondary non-responder due to previous injection of botulinum toxin preparations
- •(8) Patients for whom one or more weeks have not passed since the last administration of anticoagulants (heparin, warfarin, etc.) by the date of the screening test (antiplatelet drugs are permitted)
- •(The screening test can be conducted on the same day of the next week or later after the last administration)
- •(9) Dysphagia scale >= 3: sever, with swallowing difficulties and requiring a change in diet
- •(10) Patients who need to perform the applicable prohibited concomitant treatment after the date of the screening test and until the completion of main period (excluding observation period after main period) or the completion of the final termination visit
- •(11) Patients whose dosage or administration of the applicable concomitant restricted drug(s) was changed in the last one week before the screening test (the screening test can be conducted on the same day of the next week or later after changing the dosage or administration), or patients whose dosage or administration of the applicable concomitant restricted drug(s) needs to be changed until the completion of the main period (excluding observation period thereafter)
- •[Exclusion criteria applicable only to Group A]
- •(12) Patients with tardive torticollis
- •(13) Patients who only have symptoms of retrocollis, or among patients with symptoms other than retrocollis, patients with a TWSTRS - severity score for retrocollis >= 2 at the screening test
结局指标
主要结局
-
Change from baseline in the TWSTRS- Total score at 4 weeks after the first injection
次要结局
- TWSTRS-total score
- Modified Tsui scale sub scale D
研究者
相似试验
招募中
不适用
An open-label, uncontrolled, single-arm study of NT 201 in patients with spasticity in children.Upper limb spasticity or Lower limb SpasticityjRCT2051240254Teijin Pharma Limited44
进行中（未招募）
不适用
An open-label, uncontrolled, single-arm study of NT 201 in patients with BlepharospasmBlepharospasmjRCT2031230711Teijin Pharma Limited25
招募中
不适用
A non-randomized, open-label, single arm study to evaluate the effect of Yokukansan on the dispositions of donepezil hydrochloride and risperidone (clinical pharmacokinetic analysis)Dementia or SchizophreniaJPRN-UMIN000026273Kumamoto University30
进行中（未招募）
1 期
ivolumab after selective internal radiation therapy using SIR-Spheres to treat patients with primary liver cancer: a safety and efficacy studyMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hepatocellular carcinomaEUCTR2017-000232-34-ESClínica Universidad de Navarra/Universidad de Navarra42
招募中
不适用
An open-label, single arm study assessing the usefulness of forward-viewing echoendoscope and difficulty factors for specimen collection in endoscopic ultrasound-guided fine-needle aspiration of gastric subepithelial lesionsgastric subepithelial lesionJPRN-UMIN000044549Department of Endoscopy, Fukushima Medeical University Hospital48